MEDFORD, Mass. (October 13, 2026) – Wyzer Biosciences will relocate next month from 85 Bolton Street in Cambridge to Cummings Properties’ Boston Avenue innovation campus in Medford. The firm’s new headquarters encompasses 5,800 square feet of administrative and laboratory space.
Founded in Cambridge in 2011, Wyzer provides customized, end-to-end DNA sequencing and preparation services for the biopharma, biotech, and academic research sectors.
Cummings Properties leasing director Steve Cusano worked with JLL vice president, lab planning and operations Marc Consalvi on the lease.
“Medford offers many of the conveniences that make Cambridge and Boston attractive to growing life sciences companies, while providing a compelling value proposition,” said Cusano. “Wyzer will remain close to the region’s robust science and tech communities while gaining additional space to support its continued organic growth.”
Wyzer’s new location places the company among a growing concentration of science and technology firms on Boston Avenue. In addition to multiple labs operated by Tufts University, its new neighbors include Lithios, Morphoceuticals, Myro Therapeutics, Sunflower Therapeutics, and Unravel Biosciences.
The Medford innovation campus features move-in-ready lab and office space with upgraded finishes, free covered parking, and on-site MBTA bus access. The Green Line extension, as well as numerous eateries, shops, and other conveniences, are within close walking distance.
Cummings Properties’ 11 million square feet of commercial real estate accommodates a diverse range of businesses, including offices, healthcare facilities, restaurants, retail storefronts, warehouses, labs and clean rooms, and executive suites. Its in-house design, construction, and property management teams provide businesses with streamlined, end-to-end support for their commercial real estate needs. More information is available at www.cummings.com.
Wyzer Biosciences provides industry partners with custom DNA preparation, specialized microbiology services, and end-to-end Sanger and Next Gen DNA sequencing. Its team of experienced scientists has more than 100 years of combined experience in sequencing and more than 60 related publications. Additional information is available at wyzerbio.com.